Acute decompensation of chronic heart failure and renal dysfunction. Diagnosis and treatment

Глизер, С Л; Штегман, О. А.; Петрова, М. М.

doi:10.29001/2073-8552-2020-35-2-35-43

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite constant advances in science and technology, as well as in the treatment methods and medical equipment used for CHF, there has been no reduction in the morbidity and mortality from this disease. Hence there is a need to further improve the early detection and diagnosis of CHF, thereby allowing preventive treatment measures [12,13]. Currently, the commonly used clinical diagnostic markers are B-type brain natriuretic peptide and N-terminal B-type brain natriuretic peptide.…”

Section: Discussionmentioning

confidence: 99%

Serum Levels of Hcy, sST2 and CA-125 in CHF Patients and Their Correlation with Cardiac Function Classification

Ma,

Zhang,

2023

HSF

View full text Add to dashboard Cite

Background: The relationships between serum levels of homocysteine (Hcy), soluble stromelysin 2 (sST2), and tumor-associated cancer antigen 125 (CA-125) and heart failure requires further investigation. The aim of the present study was to evaluate the levels of Hcy, sST2 and CA-125 in patients with congestive heart failure and to correlate these with cardiac function, thereby providing a reference for the clinical diagnosis and treatment of heart failure. Methods: Seventy patients with chronic heart failure (CHF) diagnosed between August 2020 and July 2022 were classified into heart failure groups II (n = 25), III (n = 23) and IV (n = 22). Seventy individuals with normal physical examination results were selected as the healthy group. Serum Hcy, sST2 and CA-125 levels for all participants were evaluated and correlated with each other and with cardiac function classification. The diagnostic value of individual Hcy, sST2, CA-125 levels for CHF was evaluated, as well as a combination of these factors. Results: Hcy, sST2, and CA-125 levels were lower in the healthy group than in the heart failure group. Moreover, a progressive increase in Hcy, sST2, and CA-125 levels were observed in heart failure groups II, III, and IV. Individual Hcy, sST2 and CA-125 levels, as well as a combination of these factors, were significantly correlated with cardiac function classification (p < 0.05). Hcy, sST2 and CA-125 levels each showed diagnostic value for CHF, with the three combined having the best diagnostic value. Conclusions: Abnormally high levels of Hcy, sST2 and CA-125 occur in CHF patients and are positively correlated with cardiac function classification. Individual levels of these factors, and particularly a combination of the three, show good sensitivity and specificity for CHF diagnosis that could be widely used in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%